High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification

Table 1 Concise overview table of patient characteristics, tissue collection and data metrics of this study

Patient	Histology	FIGO stage*	N of samples	Sample site	Tissue type	Sample_ID°	Total n cells	Median n genes/cell	Median n UMIs/cell	Sequencing saturation
Patient 1	HGSTOC	IIIC	5	Omentum	Tumour	P1TOm	1403	3109	11,544	73.50%
				Omentum	Non-tumour	P1NOm	879	2751	10,090	82.50%
				Peritoneum	Non-tumour	P1NP	1045	1162	2867	93.90%
				Peritoneum	Tumour	P1TP	1249	1192	2958	92.90%
				Ovary	Tumour	P1TOv	1419	3407	12,854	78.20%
Patient 2	HGSTOC	IVB	1	Peritoneum	Tumour	P2TP	2482	2064	7133	81.10%
Patient 3	HGSTOC-CCC	IVB	1	Peritoneum	Tumour	P3TP	3537	2838	9311	63.00%
Patient 4	HGSTOC	IC1	2	Ovary	Tumour	P4TOv	395	2119	7896	87.50%
Patient 4	HGSTOC	IC1	2	Ovary	Non-tumour	P4NOv	3044	1527	5061	67.50%
Patient 5	HGSTOC	IVB	1	Peritoneum	Tumour	P5TP	1343	4610	23,655	74.70%
Patient 6	HGSTOC	IIIC	1	Peritoneum	Tumour	P6TP	2060	4008	20,327	62.90%
Patient 7	HGSTOC	IVB	1	Peritoneum	Tumour	P7TP	1627	1526	5348	63.60%

HGSTOC high-grade serous tubo-ovarian carcinoma, CCC clear cell carcinoma, N number, UMI Unique Molecular Identifier
* FIGO stage = disease stage determined by the International Federation of Gynaecology and Obstetrics (FIGO) 2014
° Sample_ID = code attributed to every sample containing 3 elements: (1) patient number (P1–P7), (2) tissue type (T = tumour, N = non-tumour) and (3) sampling site (Om = omentum, Ov = ovary, P = peritoneum)

ISSN: 1756-994X